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ABSTRACT
BACKGROUND: Many therapeutic strategies have been proposed to treat liver
fibrosis, but no drugs have been proved effective. Matrix metalloproteinases (MMPs)
have been reported to playa role in some cellular cascades of hepatic inflammation and
fibrosis.
OBJECTIVE: The purpose of this study was to investigate whether silymarin and
pentoxifylline (PTX) have hepatoprotective and antifibrotic effects in experimental
hepatic fibrosis.
METHODS: Sprague-Dawley rats were divided into 4 groups: silymarin group
(silymarin 4 mg/kg . d-1 orally, common bile duct ligation [CBDLJ); PTX group
(PTX 2 mg/kg . d-1 intraperitoneally, CBDL); sham group (common bile duct [CBDJ ex-
ploration only); and control group (saline 1 mLid orally, CBDL). The CBD was explored
and dissected sufficiently to allow passage of a 3/0 silk suture via midline laparotomy.
On day 10, all animals were euthanized via cervical dislocation. Then, 5-cm3 liver
samples from the right lobe were removed for histomorphologic evaluation and 3-mL
blood samples were taken via cardiac puncture for biochemical analyses. Apoptosis
was determined using the terminal deoxynucleotidyltransferase-biotin nick end-label
(TUNEL) staining method. Plasma levels of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and y-glutamyltransferase; total and indirect bilirubin con-
centration; hepatic MMP-1 and -2 and tissue inhibitor of MMP (TIMP)-l and -2
activity; and transforming-growth factor (TGF)-l\ concentration were measured. Col-
lagen content was determined by measuring hydroxyproline in liver samples. Malon-
dialdehyde (MDA) was used to estimate lipid peroxidation.
RESULTS: Thirty-two adult male Sprague-Dawley rats were divided into 4 groups:
silymarin group (n = 7), PTX group (n = 7), sham group (n = 9), and control group
(n = 9). Compared with the control group (14.6 [2.44J), mean (SD) hepatocyte apop-
tosis (as measured by the ratio of TUNEL-positive cells) was significantly suppressed
in the silymarin group (1.2 [O.13); P = 0.001) and the PTX group (3.8 [O.34); P =
0.001). Mean (SD) MMP-2 activity in the silymarin group (57.35 [9.89) pg/mL; P =
0.04) and the PTX group (46.88 [9.56) pg/mL; P = 0.04) was significantly lower than
that observed in the control group (232.32 (79.76) pg/mL). Compared with the con-
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trol group (1.37 [0 .38} pg/rnl.), TIMP-2 activity was significantly lower in the sily-
marin group (0.55 [0.l3} pg /mL; P = 0.04) and the PTX group (0.42 [0.09} JIg/mL;
P = 0.01). Compared with the control group (909.17 [I17.35} pg/rnl.), TGF-I\ was
significantly lower in the silymarin group (518.24 [30.34} pg/mL; P = 0.01) and the
PTX group (519.57 [47.27) ug /ml.; P = 0.01). Histomorphologic changes were sig-
nificantly greater in the sham group than in the silymarin and PTX groups: hemor-
rhage (2.44 [0.29} vs 1.29 [0 .18} and 1.57 [0 .20}, respectively; both, P = 0.04);
sinusoidal dilatation (2.22 [0.22} vs 1.5 7 [0.20} and 1.71 [0.18}; both, P = 0.04);
presinusoidal polymorphonuclear cell infiltration (3.44 [0.24} vs 2.57 [0 .20} and
2.14 [0.26}; P = 0 .03 and P = 0.008, respectively); and inflammation (3.44 [0.24} vs
2.57 [0.20} and 2.14 [0.26}; P = 0 .03 and P = 0.008, respectively). In the control
group, all biochemical markers were elevated, supporting the presence of liver injury.
Compared with the control group (630.00 [46.80} VlL), plasma AST activity was sig-
nificantly lower in the silymarin group (443.11 [78.73}; P = 0.04) and the PTX group
(349.42 [34.00}; P = 0.03). Compared with the control group (191.12 [32 .93} VIL),
plasma ALT activity was significantly lower in the silymarin group (86 .14 [4 .97); P =
0.04) and the PTX group (84 .14 [I1.21}; P = 0 .04). MDA concentration was signifi-
cantly lower in the silymarin group compared with the control group (0.08 [G.O'l ] vs
0.22 [0.03} nmol/mL; P = 0.004) ; MDA was also significantly lower in the silymarin
group than in the PTX group (0 .11 [0.02}; P = 0 .0 3).
CONCLUSIONS: Silymarin and PTX were associated with lower histopathologic
liver damage, hepatocyte apoptosis, and regulation of extracellular matrix proteins.
Lipid peroxidation in hepatocytes was significantly lower in the silymarin group com-
pared with the PTX group. Silymarin and PTX appeared ro have hepatoprotective
effects in this experimental liver fibrosis model, but further clinical and experimental
studies are needed. (Curr TherRes Clin Exp. 2008;69:488-502) © 2008 Excerpta Medica
Inc.
KEY WORDS: matrix metalloproteinases, MMP-1, MMP-2, tissue inhibitor of
matrix metalloproreinases, TIMP-1, TIMP-2, experimental liver fibrosis, apoptosis.
INTRODUCTION
Liver cirrhosis is the terminal stage of a variety of chronic active liver diseases with
different etiologies, among which nutritive-toxic, alcohol, viral, immunologic, and
parasitic injuries prevail.' Liver injury is associated with the activation of hepatic stel-
late cells (HSCs). The resulting secretion of matrix by activated HSCs results in liver
fibrosis and ultimately in cirrhosis.
Cirrhosis and fibrosis are both irreversible and may progress.? Hepatic fibrogenesis
is a dynamic unity of liver cells and extracellular matrix (ECM) proteins. Major changes
in the quality and the amount of hepatic ECM with hepatocellular cells, HSCs, and
depot cells, and activation of lipocytes playa major role in regeneration of ECM.2
Studies have reported that the excessive accumulation of ECM in liver is a dynamic
and bidirectional process that is mainly regulated by HSCs that become activated and
develop a myofibroblast-like phenotype that is associated with increased proliferation
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and collagen synthesis.v-' Several in vitro studies found that HSC activation results
from the complex interplay of different variables, such as cytokines, growth factors,
oxidative stress, and modification of sodium/hydrogen ion-exchange activity.t-?
Although traditionally viewed as irreversible, reversibility of liver fibrosis has been
described.> Targeting antifibrotic drugs to HSCs is currently a promising strategy for
blocking fibrotic processes leading to liver cirrhosis. Therefore, finding a proper
pharmacotherapeutic treatment for liver fibrosis is considered a priority.P
Matrix metalloproteinases (MMPs) released from hepatocyres and Kupffer cells can
degrade multiple ECM components.v" Interstitial collagenase MMP-l is released
from the liver. MMP-2 and MMP-14 have interstitial collagenic activity that de-
creases in chronic liver disease, resulting in collagen accumularion.v" Tissue inhibitor
of MMP (TIMP)-l and TIMP-2 activity increase in association with hepatic fibro-
sis.>? Increasing the TIMP/MMP ratio induces hepatic fibrosis through MMP in-
hibition of the degradation of ECM in liver. As a result, overexpression of ECM by
activated liver cells, reduction of MMP activation, and inhibition of active MMPs by
TIMPs induces fibrogenesis. Therefore, removing activated liver cells by apoptosis
may have a therapeutic effect, stopping or even reversing the fibrogenic process
in liverJ-9 However, a study in patients with chronic hepatitis due to hepatitis C virus
infection found that hepatic MMP-2 and MMP-9 activity in leukocytes increased,
whereas TIMP-2 activity in mononuclear leukocytes decreased.l? The degree of in-
flammation and fibrosis did not correlate with either MMP-9 or TIMP mRNA
production.
Hepatic scarring is the result of a dynamic process that balances fibrogenesis and
fibrolysis.l ' Fibrogenesis is a result of excess synthesis and deposition of ECM. The
early phase of fibrogenesis occurs in the subendothelial space ofDisse. The cells in this
region include endothelial cells, hepatocyres, Kupffer cells, and HSCs. HSCs are the
main source of extracellular matrix."! Quiescent HSCs transform into myofibroblast-
like cells and proliferate. ll •12 Several cytokines are thought to be involved in the
signaling of this process: fibroblast growth factor, transforming growth factor
(TGF)-13l' interleukin-l and -2, tumor necrosis factor (TNF), monocyte chemo-
attractant protein, platelet-derived growth factor (PDGF), and endothel iri-Lv'f
Fibrolysis relies on collagenases, such as metalloproteinases. TIMPs are found in
pathologic conditions, such as cirrhosis. l1 - 13
There are 2 types of liver fibrosis: portal/septal fibrosis and perisinusoidal fibro-
sis."! Portal fibrosis, the most prominent morphologic feature in cirrhosis, represents
a major architectural disturbance. Although perisinusoidal fibrosis is observed in cir-
rhosis, it can be the unique cause of portal hypertension (ie, vitamin A intoxication). 11
Perisinusoidal fibrosis involves overproduction of ECM components, which leads to
the capillarization of sinusoids. Hepatic ECM was originally considered a metaboli-
cally inert material that serves as a framework for the functionally important paren-
chyma. 11- 13 To the contrary, ECM of liver and of other epithelial-mesenchymal organs
is a complex assembly of macromolecules that rapidly undergoes remodeling after
injury. The molecules of hepatic ECM have been subdivided into collagens, non-
collagenous glycoproteins, glycosaminoglycans, proteoglycans, and elastin.l '
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Silymarin is a standardized extract of the milk thistle (Silybum marianum) whose
main active compounds are the flavonoids silybin, silychristine, and silydianin, with
silybin accounting for -60% of the composirion.l? Silymarin has been reported to
possess heparoprotective properties in both in vitro and in vivo studies. 15- 17 In liver
fibrosis, silybin was found to reduce activation and proliferation of isolated and cul-
tured HSCs and to reduce collagen accumulation in experimental liver fibrosis in
rats. 18-20 Silymarin is a potent antioxidant that inhibits lipid peroxidation in hepato-
cytes. 20-22 It has also been reported to have anti-inflammatory activities mediated by
alteration of hepatic Kupffer cell funcrion.F'
Pentoxifylline (PTX) may target fibrotic liver. 5,6 ,14- 16 Its antifibrogenic and anti-
inflammatory effects on activated HSCs have been reported. 24-27 PTX reduces the
transdifferentiation of HSCs to myofibroblasts and inhibits HSC proliferation.24 ,25
PTX has also been reported to reduce the fibrogenic effect of TGF-~ on HSCs by in-
terfering with p38 mitogen-activated protein kinase and extracellular signal-regulated
protein kinase 1/2 pathways, thereby decreasing hepatic procollagen type 1 mRNA
expression. However, profibrotic effects of PTX on Kupffer cells have been report-
ed. 26,27 The objective of this study was to investigate the hepatoprotective and antifi-
brotic effects of silymarin and PTX in a rat model of liver fibrosis.
MATERIALS AND METHODS
ANIMALS
Adult male Sprague-Dawley rats (weight, 180-200 g) were kept on an artificial
12-hour light-dark cycle and given access to standard rat chow and water ad libitum,
according to the National Institutes of Health publication Guide for the Care and Use
of Laboratory Animals. 5,7 ,16 Experiments were carried out in compliance with guide-
lines prescribed by the Institutional Animal Care and Use Committee of Ege Univer-
sity School of Medicine (Ege, Turkey). The Research Ethics Committee of the School
of Medicine of Ege University approved the study protocol.
EXPERIMENTAL DESIGN AND SURGICAL PROCEDURE
The animals were allocated, using a randomization table, into 4 groups: PTX
group (PTX 2 mg/kg . d-1 intraperitoneally, common bile duct ligation [CBDL});
silymarin group (silymarin 4 mg/kg . d-1 orally, CBDL); sham group (common bile
duct [CBD} exploration only); and control group (saline 1 mLld orally, CBDL). All
animals were anesthetized using vaporized isoflurane (Abbott Laboratories, North
Chicago, Illinois). CBDL was used to create extrahepatic obstruction that would cause
cholestasis, liver damage, and fibrosis, as previously described in the Iiterature.P' We
preferred the CBDL method, as it is now being used for experimental liver fibrosis
models and is easy to perform, especially in rats. A midline laparotomy was performed
and the CBD was dissected sufficiently to allow passage of a 3/0 silk suture. Sham-
operated animals underwent an identical laparotomy, except that CBD was merely
identified without ligation. On day 10, all animals were sacrificed via cervical disloca-
tion. The liver and CBD were exposed through a midline incision. Tissue samples
(5 ern") from the right lobe were removed for histomorphologic evaluation and blood
49'
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samples (3 mL) were taken via cardiac puncture for biochemical analyses. Plasma
levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) , and
y-glutamyltransferase (GGT); serum concentrations of total and indirect bilirubin;
tissue activity of MMP-l and -2 and TIMP-l and -2; and TGF-J31 and hepatic
hydroxyproline concentrations were measured. Malondialdehyde (MDA) concentra-
tion was used to estimate lipid peroxidation. A technician who was blinded to treat-
ment group analyzed the liver and blood samples.
Tissue Collection and Fixation
All samples were fixed in a 10% formalin solution. Samples were then washed with
tap water and soaked in a series of 50%, 60%, 70%, 80%, and 90% ethanol for
30 minutes and then in 95 % and 100% ethanol for 1 hour. They were then held in a
solution of 100% ethanol and xylene 0: 1 ratio) for 30 minutes, embedded in paraffin,
and held at 60°C for 1 hour to create paraffin blocks.
Hydroxyproline Concentration and Collagen Content
Tissue hydroxyproline concentration was determined using a modification of the
method described by Chiariello et al. 29 Tissue samples were dried to a constant weight
at 60°C and acid-hydrolyzed in sealed ampules overnight in 6N hydrochloride with
6 mL/100 mg dry tissue. Samples were then filtered through Whatman 3 filter paper
(Sigma-Aldrich, St. Louis, Missouri) and dried under a vacuum. Dried samples were
suspended in 4 mL of distilled water, and the pH was adjusted to 6.0 with IN sodium
hydroxide. Isopropanol (4 mL) was added, and 60 L of this solution was increased
to 400 L by adding acetate-citrate-isopropanol (1:1:1). After incubation at 25°C for
5 minutes, 100 L of oxidant buffer and 1300 L of Ehrlich's reagent were added. After
incubation at 60°C for 30 minutes, absorption at 558 nm was measured. Tissue hydroxy-
proline concentrations were calculated from a standard curve using hydroxyproline concen-
trations in the range of 0.5-5.0 g. Data were expressed as pg/ml, of dry tissue weight.v"
Histochemical Observation
Transverse sections (5 prn) were taken from the paraffin blocks using a rotary
microtome (RM 2135, Leica Microsystems, Wetzlar, Germany) and prepared for both
histochemical and terminal deoxynucleotidyltransferase-biotin nick end-label
(TUNEL) staining. Sections dewaxed at 60°C overnight were immersed in xylene for
1 hour and then rehydrated through a graded ethanol series 000%, 95%, 80%, 70%,
and 60%) for 2 minutes at each concentration. They were then washed in tap water.
After 2 minutes of staining with hematoxylin and eosin (HE) (01562E, Surgipath
Europe Ltd., Bretton, Peterborough, United Kingdom), the sections were rewashed
for 5 minutes to prevent overstaining. Thereafter, sections were stained with HE
01602E (Surgipath Europe Ltd.) according to the company's prorocol.I! Slides were
mounted using a mounting medium (Entellan'", UN 1866, Merck, Darmstadt, Ger-
many) and covered with glass coverslips prior to being photographed under light
microscopy (BX-40, Olympus America Inc., Melville, New York) by one investigator
(S.v.), who was blinded to the treatment protocol.
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The liver samples were stored to protect them from light. Tissue sections were fixed
in 10 % neutral buffered formalin and embedded in paraffin. Paraffin sections were
stained with HE and were examined and scored by a pathologist who was blinded to
the treatment protocol. Histopathologic evaluation was performed twice in 4 sections
per slide for each animal.
DETECTION OF ApOPTOTIC CELL DEATH IN SITU USING
THE TUNEL METHOD
Fragmentation of DNA in the nucleus is one of the first morphologic changes
of the apoptotic process . To detect the fragmentation in histologic sections , we
used a commercial TUNEL-method kit (DeadEnd Colorimetric TUNEL System Kit,
Roche-USA, Nutley, New Jersey) according to the manufacturer's instructions.32,33
Paraffin was removed from the sections using xylene; the sections were then rehy-
drated and postfixed with 4 % paraformaldehyde for 10 minutes. They were then in-
cubated with proteinase K 20 ug/rnl, for 10 minutes and rinsed in distilled water for
5 minutes. Endogenous peroxidase activity was inhibited with 3% hydrogen perox-
ide . The sections were incubated in equilibration buffer for 10 to 15 seconds and then
in terminal deoxynucleotidyl transferase (TdT) enzyme in a humidified atmosphere at
37°C for 60 minutes. They were subsequently placed in prewarmed working-strength
stop/wash buffer at room temperature for 10 minutes and incubated with antisrrepravidin-
peroxidase for 45 minutes. Each step was separated by careful washing in phosphate-
buffered saline. Staining was done with 3,3'-diaminobenzidine and counterstaining
was performed in Mayer's hematoxylin. The slides were examined independently by
one of the authors (S.Y), who was blinded to the results of the routine histologic ex-
amination. Approximately 100 TUNEL-positive cells per case were counted ran-
domly in chosen fields . The percentage of apoptotic cells stained brown was deter-
mined. Cells in areas with necrosis or poor morphology or cells in the margins of
sections were not analyzed. As negative staining, control for TdT enzyme was omitted
during the tailing reactions.32•33
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS version 10.0 (SPSS Inc., Chicago,
Illinois). Data were expressed as mean (SEM). The Mann-Whitney U test was used for
nonparametric data, and the t test and I-way analysis of variance (ANOVA) with the
Tukey test were used for parametric data. The mean differences in hepatic hydroxy-
proline content and MDA concentration among groups were analyzed using I-way
ANOVA and confirmed using the Student-Newman-Keuls test. Histomorphologic
data for TUNEL positivity were compared using I-way ANOVA. P < 0.05 was con-
sidered statistically significant.
RESULTS
EXPERIMENTAL SUB.JECTS
Thirty-two adult male Sprague-Dawley rats were assigned to 1 of 4 groups: silymarin
group (n = 7), PTX group (n = 7), sham group (n = 9), and control group (n = 9) .
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MATRIX METALLOPROTEINASE AND TISSUE INHIBITOR OF MATRIX
METALLOPROTEINASE ACTIVITY
The effects of liver injury on ECM proteinase and collagen cascade via tissue
MMP-1 and -2 and TIMP-1 and -2 activity and TGF-f3 1 and hydroxyproline con-
centration were evaluated (Table I). Mean (SEM) MMP-l activity was similar in
all groups. MMP-2 activity was significantly lower in the silymarin and PTX
groups compared with the control group (57.35 [9.89} and 46.88 [9.56} vs
232.32 [79.76} pg/mL, respectively; both, P = 0.04). MMP-2 activity was simi-
lar in the silymarin and PTX groups. Hepatic TIMP-1 activity was similar in all
groups. Compared with the control group (1.37 [0.38} }lg/mL), hepatic TIMP-2
activity was significantly lower in the silymarin group (0.55 [O.B} pg/rnl.; P = 0.04)
and the PTX group (0.42 [0.09} pg/rnl.; P = 0.01), but no statistically significant differ-
ence was found between the silymarin and PTX groups (Figures 1-3).
The highest TGF-f3 1 concentration was found in the control group (909.17
[117.35}). Compared with the control group, TGF-f3 1 concentration was significantly
lower in the silymarin and PTX groups (518.24 [30.34} and 519.57 [47.27} }lg/mL,
respectively; both, P = 0.01). There was no significant difference in TGF-f31 concen-
tration between the silymarin and PTX groups (Table I).
Tissue hydroxyproline concentration was highest in the control group
(0.70 [0.08} ug/rnl.). The sham group (0.26 [0.04} pg/rnl.) had significantly lower
hydroxyproline concentration compared with the silymarin group (0.60 [0.14} pg/mL;
P = 0.04), the PTX group (0.58 [0.10} pg/mL; P = 0.04), and the control group
(0.70 [0.08} pg/mL; P = 0.01). The hydroxyproline concentration was not signifi-
cantly different between the silymarin or PTX groups compared with the control
group.
Table I. Mean (SEM) matrix metalloproteinase (MMP) and tissue inhibitor of MMP
(TIMP) activity and transforming growth factor (TGF)-~1 and hydroxyproline
concentration after 10 days of treatment in the silymarin, pentoxifylline (PTX),
sham, and control groups (N = 32). All data are pgjmL.
Silymarin PTX Sham Control
Variable (n = 7) (n = 7) (n =9) (n =9)
MMP-l 0.17 (0.02) 0.15 (0.01) 0.17 (0.02) 0.22 (0.02)
MMP-2 57.35 (9.89)* 46.88 (9.56)* 80.05 (19.6) 232.32 (79.76)
TIMP-l 0.53 (0.05) 0.45 (0.10) 0.45 (0.05) 0.74 (0.26)
T1MP-2 0.55 (0.13)* 0.42 (0.09)* 0.43 (0.05) 1.37 (0.38)
TGF-~l 518.24 (30.34)* 519.57 (47.27)* 571.44 (42.17) 909.17 (117.35)
Hydroxyproline 0.60 (0.14)t 0.58 (0.10)t 0.26 (0.04)* 0.70 (0.08)
*p < 0.05 versus control.
tp < 0.05 versus sham.
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Figure 1. Mean (SO) and range of matrix metalloprotelnase (MMP)-1 and tissue inhibitor
of MMP (TIMP)-1 activity by group In adult male Sprague-Dawley rats. PTX =
pentoxifylline. *Outlier data with sUbject number.
HISTOMORPHOLOGv/ApOPTOSIS
Dat a for hi stomorphologic changes in liver seen under light m icroscopy are shown
in Table II. In the sham group , the heparocyres were normal, active cells had vesicular
nuclei , and cytoplasm was basoph il ic. No pol ymorph nuclear leukocyte (PNL) infil-
tration was observed in the sham group. In the contro l group, hepatocyte cyro-
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Figure 2. Mean (SO) and range of matrix metalloprotelnase (MMP)-2 activity by group in
adult male Sprague-Dawley rats. PTX =pentoxifylllne.
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Figure 3. Mean (SO) and range of tissue Inhibitor of matrix metalloprotelnase (TIMP)-2
activity by group In adult male Sprague-Dawley rats. PTX = pentoxifylline.
plasm was basophilic and nuclei were picnotic. Moreover, severe PNL infiltration
was observed in periportal and sinusoidal areas. The ratio of TUNEL-positive cells
was 1.2 (0.13), 3.8 (0.34),0.3 (0.15), and 14.6 (2.44) in the silymarin, PTX, sham,
and control groups, respectively. The ratio of TUNEL-positive cells in the control
Table II. Mean (SEM) data for hlstomorphologlc changes seen under light microscopy
after 10 days of treatment In the silymarln, pentoxifylline (PTX), sham, and
control groups (N = 32).
Silymarin PTX Sham Control
Variable (n = 7) (n = 7) (n = 9) (n = 9)
CHM 1.43 (0.20) 2.00 (0.22)*t 2.22 (0.22)* 1.11 (0.11)
Hemorrhage 1.29 (0.18)t 1.57 (0.20)*t 2.44 (0.29) 1.00 (O)t
Sinusoidal
dilatation 1.57 (0.20)*t 1.71 (0.18)* 2.22 (0.22)* 1.00 (0)
PPCI 2.57 (0.20)t 2.14 (0.26)t 3.44 (0.24) 1.00 (O)t
Necrosis 1.00 (0)1' 1.71 (0.29)* 1.44 (0.24) 1.22 (0.15)1'
Inflammation 2.57 (0.20)t 2.14 (0.26)t 3.44 (0.24) 1.00 (O)t
CHM = changes in hepatocyte morphology; PPCI = presinusoidal polymorphonuclear cell infiltration.
*p < 0.05 versus control.
t p < 0.05 versus sham.
,.P < 0.05 versus PTX.
496
E. KARA ET AL.
group was significantly higher compared with the sham, silymarin, and PTX groups
(all, P = 0.001). PTX and silymarin were both associated with significantly reduced
apoptosis compared with the control group; silymarin (1.2 (0.13}) reduced apoptosis
significantly, more than PTX (3.8 (0.34}; P = 0.04).
Changes in hepatocyte morphology (CHM), hemorrhage, sinusoidal dilatation,
presinusoidal polymorphonuclear cell infiltration (PPCI), necrosis, and periportal in-
flammation were evaluated using light microscopy (Table II). Compared with the
control group (1.11 (O.ll}), CHM score was significantly higher in the PTX group
(2.00 (0.22}; P = 0.008) and the sham group (2.22 (0.22}; P = 0.002). CHM score
was not significantly different in the silymarin group compared with the PTX group.
Compared with the sham group (2.44 (0.29}), hemorrhage was significantly less se-
vere in the silymarin group (1.29 (0.18}; P = 0.04), the PTX group (1.57 [O.20};
P = 0.04), and the control group (1.00 [OJ; P < 0.001). There was no significant
difference between the silymarin group and the PTX group. The number of ani-
mals with sinusoidal dilatation was significantly greater in the silymarin group
(1.57 {0.20}; P = 0.04), the PTX group (1.71 [O.18}; P = 0.04), and the sham group
(2.22 [0.22}; P < 0.00l), compared with control group (1.00 [OJ); no statistically
significant difference was found between the silymarin and PTX groups. Compared
with the sham group (3.44 [0.24}), PPC! was significantly less severe in the silymarin
group (2.57 [0.20}; P = 0.03), the PTX group (2.14 [0.26}; P = 0.008), and the con-
trol group (1.00 [OJ; P < 0.001). No statistically significant difference was found in
PPCI in the silymarin group compared with the PTX group. Necrosis was signifi-
cantly greater in the PTX group (1.71 [O.29}) compared with the silymarin group
(1.00 [OJ; P= 0.007) and the control group (1.22 [O.15}; P :: 0.048). Compared with
the sham group (3.44 [0.24}), inflammation was significantly less severe in the
silymarin group (2.57 [O.20}; P = 0.03), the PTX group (2.14 [0.26}; P = 0.008),
and the control group (1.00 [OJ; P < 0.001).
LIVER FUNCTION AND LIPID PEROXIDATION
Biochemical parameters showing hepatic function and the status oflipid peroxidation
analyzed via MDA concentration are shown in Table III. Liver function was monitored
by measuring plasma total and indirect bilirubin concentration and AST, ALT, and
GGT activity. In the control group, all biochemical markers were elevated after CBDL,
indicating liver injury. Bilirubin concentrations were significantly lower in the sham
group compared with the control group-total bilirubin (0.52 [0.07} vs 9.24 [O.63} UIL;
P < 0.001) and indirect bilirubin (0.48 [O.06} vs 3.79 [0.18}; P < 0.001). Total and
indirect bilirubin concentrations in the silymarin group and the PTX group were not
statistically significantly different compared with the control group. These values were also
similar between the silymarin and PTX groups. AST activity in the sham group was sig-
nificantly lower compared with the control group (100.77 [8.68} vs 630.00 [46.80} UIL;
P = 0.001). AST activity was also significantly lower in the silymarin group
(443.11 [78.73}; P = 0.04) and the PTX group (349.42 [34.00}; P = 0.03). AST activi-
ty was not significantly different' between the silymarin and PTX groups. Compared
with the sham group (35.66 (2.34}), ALT activity was significantly higher in the sily-
497
CURRENT THERAPEUTIC RESEARCH
Table III. Mean (SEM) values of liver function tests after 1.0 days of treatment in the
silymarin, pentoxifylline (PYX), sham, and control groups (N =32).
Silymarin PTX Sham Control
Variable (n = 7) (n = 7) (n = 9) (n = 9)
Total bilirubin, 8.85 (0.63)* 8.95 (0.54)* 0.52 (0.07)t 9.24 (0.63)
U/L
Indirect bilirubin, 3.35 (0.29)* 3.59 (0.18)* 0.48 (0.06)t 3.79 (0.18)
U/L
AST, U/L 443.11 (78.73)*t 349.42 (34.00)*t 100.77 {8.68)t 630.00 (46.8)
ALT, U/L 86.14 (4.97)*t 84.14 (11.21)*t 35.66 (2.34) 191.12 (32.93)*
GGT, U/L 22.95 (4.03)* 27.75 (4.17)* 3.53 (0.73) 67.38 (11.35)*
MDA, nmol/ml, 0.08 (O.Ol)tt 0.11 (0.02)t 0.14 (0.02)t 0.22 (0.03)
AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = y-glutamyltransferase;
MDA = malondialdehyde.
"P < 0.05 versus sham.
t p < 0.05 versus control.
t p < 0.05 versus PTX.
marin group (86.14 [4.97) UIL; P < 0.001), the PTX group (84.14 {l1.2l}; P < 0.001),
and the control group (191.12 [32.93J; P < 0.001). ALTactivity was significantly lower
In the silymarin and PTX groups compared with the control group (both, P = 0.04).
Compared with the sham group 0.53 [O.73}), GGT activity was significantly higher in
the silymarin group (22.95 [4.03}; P < 0.001), the PTX group (27.75 [4.17); P <
0.001), and the control group (67.38 {l1.35}; P = 0.007).
Based on MDA concentrations, CBDL was associated with lipid peroxidation.
Compared with the control group (0.22 [0.03} nmol/mL), MDA concentration was
significantly lower in the silymarin group (0.08 [0.0l}; P = 0.004), the PTX group
(0.11 [0.02}; P = 0.04), and the sham group (0.14 [0.02}; P = 0.04). MDA concen-
tration was significantly lower in the silymarin group compared with the PTX group
(P = 0.03) (Table III).
DISCUSSION
Substantial progress has been made in understanding the cellular and molecular regu-
lation of hepatic fibrosis.v" Excessive accumulation of ECM in fibrotic liver diseases
is a dynamic process that is mainly regulated by HSCs, which might therefore repre-
sent the main target for antifibrotic therapies.v ? Hepatic fibrogenesis is associated
with hepatocellular necrosis and inflammation, and HSCs are regarded as the primary
target cells for inflammatory stimuli in the injured liver. 3,4
Silymarin and silybin have been reported to activate hepatocyte ribonuclease poly-
merase II, to restore the adenosinetriphosphatase activity and glutathione content,
and to prevent oxidative membrane damage. 34,35 Silymarin has been reported to pre-
vent or attenuate acute liver injury caused by carbon rerrachloride.?! paracetarnol.V
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n-galacrosarnine.P ischernia/reperfusion.v" and radiationY Two studies suggested
that silymarin prevents fibrosis induced by carbon tetrachloride.t'' However, in the rat
model and related animal models, the antifibrotic effect of silymarin may result from
its antioxidant and radical scavenging properties. In our study, the silymarin group
had a lower MDA concentration and was associated with greater suppression of lipid
peroxidation than the PTX group. Moreover, using the model of secondary biliary
fibrosis after complete CBDi, which results in progressive fibrosis in the absence of
inflammation and necrosis, silymarin was found to prevent hepatic collagen accumu-
lation,39,4o as was found in this study. Fibrosis was found to result from increased
synthesis and deposition (ie, fibrogenesis) and/or decreased degradation and removal
(ie, fibrolysis) ofECM cornponents.v' TGF-~l' a multifunctional growth factor, plays
an important role as a profibrogenic factor in chronic liver disease, triggering the
expression of procollagen I and TIMP-I, key effectors of fibrogenesis.Y TGF-~ is the
most potent fibrogenic cyrokine described for HSCs and stimulates the synthesis and
deposition ofECM components (eg, elastin, tenascin, osteonectin, biglycan, decorin, and
types I, III, and IV collagen).42,43 HSCs are a major source ofTGF-~l' but Kupffer cells,
hepatocyres, and platelets can also secrete this cytokine.41--46 In biliary fibrosis, he-
patic expression ofTGF-~, procollagen aI, and TIMP-I is highly upregulated.44--46
Our study found that hepatic TGF-~1 concentrations markedly increased in experi-
mental liver fibrosis. Treatment with both silymarin and PTX significantly decreased
TGF-~1 concentration versus control.
Hepatotoxicity may be the result of primary apoprosis.f? Hepatotoxins (eg, nitro-
samines) have been found to induce DNA fragmentation in vivo, and the formation
of apoproric bodies has been observed after treatment of animals with ethanol, di-
methylnitrosamine, and carbon terrachloride.v' Proapoptotic cyrokines (eg, TNF,
TGF-~, and PDGF) are major cytokines involved in fibrogenesis. Several studies have
examined the role of fibroblast apoptosis and the influence of cytokines generated by
the fibrogenesis cascade on hepatocyte apoptosis. An autocrine cytokine loop exists for
the fibrogenic cytokine TGF-~. Gressner et al49 found that hepatic myofibroblasts,
which are transformed HSCs, participated in hepatocyte apoptosis by paracrine loops
involving TGF-~. This is additional evidence for the perpetuation of fibrogenesis.
Iredale et apo found that HSC activation was associated with expression of the cell cycle
and apoptosis of the HSC regulatory Myc proto-oncogene protein. Conversely, in liv-
ers allowed to spontaneously recover from fibrosis, the number of apoptotic bodies
increased. These data suggest that HSC activation may be associated with inhibition
of apoptosis which is responsible for activation and proliferation of HSCs. Therefore,
the inhibition of HSC apoptosis could be a target for antifibrotic strategies. Ursode-
oxycholic acid is one of the drugs that has been found to be effective in treating pri-
mary biliary cirrhosis. 11 Silymarin and phosphatidylcholine are currently being evalu-
ated in clinical trials. However, these are not true anrifibroric agents. In our study,
silymarin and PTX both showed cytoprotective effects. As cytoprorective agents, they
work at least in part by inhibiting hepatocyte apoptosis.
This study had some limitations. Hepatic fibrosis is a complex process in which
interaction between apoptosis in HSCs and regulation ofMMPs should be studied not
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only in animals but also in humans. In this study, we measured the effects of 10 days
of drug treatment after CBDi. However, histomorphologic and biochemical changes
and the balance between other MMPs and TIMPs could also be analyzed on days 3, 7,
and 21 of treatment. This might provide varying results and deserves further investi-
gation. Different doses of silymarin and PTX in this experimental liver fibrosis model
might also be investigated.
CONCLUSIONS
Silymarin and PTX were associated with lower histopathologic liver damage, hepato-
cyte apoptosis, and regulation ofECM proteins. Lipid peroxidation in hepatocytes was
lower in the silymarin group compared with the PTX group. Silymarin and PTX
appeared to have hepatoprotective effects in this experimental liver fibrosis model, but
further clinical and experimental studies are needed.
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